



UK Delegation

Members of the UK delegation are listed here alphabetically with profiles.

Further information is available at the UK stand #68.

A list of all UK based companies attending the conference is also provided on pages 23-24, sorted by company type.



UK Trade & Investment

Also available online at: <http://beu13.biopartner.co.uk/search>

All languages - one solution

nova

Big enough to meet your needs Small enough to care

- Multilingual language based solutions
- Specialised medical translation and localisation
- Medical writing
- Medical conference interpretation
- Monthly average of 200 projects in clinical research and regulatory affairs
- Over 100 language combinations
- Certified quality:
 - ISO 9001:2008
 - UNE-EN: 15038:2006

Visit us at
**Bio-Europe
Vienna 2013**
Booth 68
UK stand

www.nova-transnet.com

nova.uk@nova-transnet.com



INDEX

	Page #
Introduction	2
Biopartner UK	3
Partner Organisations	3
UK Delegation	5
All Attending UK Companies	23

Whereas every effort has been made to ensure that the information given in this document is accurate, BioPartner UK accepts no liability for any errors, omissions or misleading statements.

Introduction

We are delighted to bring 60+ UK companies to Bio-Europe 2013, and to support an additional 150 who are independently registered. Visit us at booth 68 to find out more about UK expertise and make contact with companies attending from the UK.

The UK is one of the world's strongest and most productive Life Sciences economies; it attracts almost 10% of the world's pharmaceutical R&D funding and is acknowledged as the gateway to Europe.

At Bio-Europe 2013, we have more than 200 companies from the UK looking to forge profitable relationships. The UK is a natural trading partner for Life Sciences companies looking for innovative collaborations, access to academic excellence and entry to the European market.

The UK provides a uniquely fertile environment for the Life Sciences industry where businesses thrive. In the UK, innovation flourishes and is easy to commercialise; industry collaborates with academia and the health service; people are highly skilled and the Government is supportive.

The UK also continues to benefit from a globally admired regulatory regime, with two internationally recognised product approval agencies being based there. Small wonder, then, that the UK is a world-class trading partner in Life Sciences, as well as a leading investment location for Life Sciences businesses.

Representatives of BioPartner UK, The UK BioIndustry Association (BIA), UK Trade & Investment and the London Mayor's Office will be present and available at BIO-Europe to discuss how we can help maximise your business potential.

BioPartner UK

Lin Bateson, Executive Director

Alasdair Stamps, Executive Director

Della Bateson-Chaffe, Administrator



BioPartner UK is an independent, accredited trade organisation, promoting international partnering for trade, investment and collaborations with UK Life Sciences companies. Operating both independently and in partnership with the UK government and major UK networks and associations, BioPartner assists SMEs to exhibit overseas, and supports start-ups through the BiotechNet team of consultants. Through the BioPartnership Programme, members benefit from discounts negotiated with partner organisations and event providers, and from shared experiences.

BioPartner leads the UK Delegation at Bio-Europe 2013.

For more information see: www.biopartner.co.uk

Tel: +44 20 7193 7815

Email: info@biopartner.co.uk



Exhibiting at Booth 68

Partner Organisations

UK BioIndustry Association (BIA)

Steve Bates, Chief Executive Officer


Alastair Carrington, Business Development Executive



Established in 1989, the BIA (BioIndustry Association) exists to encourage and promote a financially sound and thriving bioscience sector within the UK economy and concentrates its efforts on emerging enterprise and the related interests of companies with whom such enterprise trades.

With over 300 members, the BIA supports a wide range of sectors, majoring on the human health benefits of the technology and represents the interests of these innovative companies to a broad section of stakeholders from patient groups to politicians, advancing its members interests both within the UK and internationally to create a healthy UK bioscience sector which benefits society.

For further information, please go to www.bioindustry.org



UK Trade & Investment (UKTI) is the government department that helps UK based companies succeed in international markets and assists overseas companies to bring high quality investment to the UK's dynamic economy. UKTI employs approximately 2,331 staff, of whom 1,279 are overseas and 1,000 are in the UK. We operate in 162 locations, in 96 markets. Staff overseas are based in British embassies and other diplomatic offices around the world. Some of the UK companies featured in this directory have been supported by UKTI grant funding under the Tradeshow Access Programme (TAP).

www.ukti.gov.uk

UK Trade & Investment Vienna

Verena Wasenegger, Trade Officer

British Embassy, Jaurèsgasse 12, 1030 Vienna

Tel: +43 (0) 1 716 13 6253

E-mail: verena.wasenegger@fco.gov.uk

UK Trade & Investment London

Christopher Parsons, International Trade Advisor

UKTI London's private sector International Trade Advisers support London based companies to develop their business internationally. This is achieved via provision of advice, training and delivery of UKTI services.

Supported by the Mayor's Export Program UKTI London is bringing a trade mission to Bio-Europe. Kit Malthouse the Deputy Mayor of London for Business and Enterprise will be meeting the mission delegates at a networking breakfast on Tuesday Nov 5th.

www.ukti.gov.uk/london

10-12 Queen Elizabeth Street, London SE1 2JN

Tel: +44 (0) 20 7234 3025

E-mail: chrisparsons@uktilondon.org.uk

UK Delegation

Members of the UK delegation are listed alphabetically with profiles, followed by a list of UK-based organisations (by company name and then by company type) attending the conference.

Whereas every effort has been made to ensure that the information given in this document is accurate, BioPartner UK accepts no liability for any errors, omissions or misleading statements, and no warranty is given or responsibility accepted as to the standing of any individual, firm, company or other organisation mentioned. Data was sourced from the Bio-Europe 2013 partnering website, and all UK companies registered up to 22nd October 2013 are included.

Advocates Pharmaceutical & Healthcare

Angelina Fisher, Director of Corporate Affairs



Advocates Ltd., Pharmaceutical & Healthcare is a global Programme Management and Technical Support Organisation based in Scotland, USA and Hong Kong. Clients include universities, virtual & start-up companies, biotechs, pharmaceutical companies, healthcare organisations and investors involved in developing cures for clinical disorders on a regional basis and with a global focus.

Since 2002, it has been our mission to “accelerate the development pathway towards healthier, extended lives through our competence and capacity to address drug development challenges”.

As a testament to this, our team of scientists, project managers & technical professionals have provided ‘hands on’ technical support to 17 drug development programmes from discovery to our clients required endpoint, all of which have met their development objectives, whilst maintaining focus on delivery of commercial objectives & investment opportunities.

Discovery to Market Key Services include:

- Grant Funding Support
- Technical Due Diligence / Investor Support
- Project Management
- Discovery & Pre-Clinical Support
- Pharmaceutical Development CMC
- Quality Management
- Regulatory Preparation, Submission & Liaison
- Operational / Commercial CMC
- Supplies / Logistics Management
- Clinical Support
- Medical Devices Expertise

Benefits to our Clients:

- Proven expertise of successfully managing development programmes
- Experienced in all compound classes, the majority of therapeutic areas and routes of administration
- Experts in CMC (Chemistry, Manufacturing & Controls)
- Credible relationships with national regulatory agencies
- Trustworthy relationships with funding bodies
- Bases in UK, USA & HK / trade in local currencies
- We care "caring is a powerful business advantage"

www.advocates.ltd.uk

Almac Group

Stephen Barr, Managing Director

Rick Dyer, Business Development Manager

Glyn Allsop, Business Development Manager

Helen McKeever, Programme Manager

Robert Grundy, Director Research Alliances, Almac Discovery Ltd

Simon Lawrence, VP, Business Development, Galen Ltd



Almac provides a comprehensive range of integrated services from research through to commercialisation. Almac is a financially stable, privately owned organisation with over 3,300 employees located within the US and UK. Over 95% of work is repeat business, testament itself to the quality, innovation, efficiency and the high level of customer satisfaction provided.

Services Offered

Almac's integrated solutions extend from research to commercialisation and include:

Biomarker Discovery & Development: Companion Diagnostic Development, Genomic Services, Bioinformatics Consultancy, Proprietary Discovery Arrays

API Services & Chemical Development: API Development & Manufacture, Peptide & Protein Technology, Accelerated First in Man Solution, Solid State Services, Isotope Chemistry, Biocatalysis

Pharmaceutical Development: Preformulation & Early Stage Development, Scale Up and Late Stage Development, Clinical Trial Manufacture, Contained Development & Manufacture

Analytical Services: Physical & Chemical Characterisation, Method Development & Validation, API & Drug Product Testing, Stability Testing

Clinical Trial Supply: Comparator Blinding, Packaging & Labelling, QP Release, Global Distribution & Supply Chain Management

Clinical Technologies: IVR / Web, ePRO, Statistical Services

Commercial Services: Manufacturing & Packaging, Product Launch & Distribution

www.almacgroup.com

Exhibiting at Booth 64

Albany Molecular Research (AMRI)

Mr Ian Trelfa, Business Development Manager



For over 21 years AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING™, a full range of value-added opportunities providing customers informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline.

AMRI (NASDAQ: AMRI), provides scientific services, technologies and products focused to the pharmaceutical industry since 1991. The Company's core business consists of a fee-for-service contract services platform encompassing drug discovery, development and manufacturing services.

www.amriglobal.com

Autifony Therapeutics

Dr Barbara Domayne-Hayman, Chief Business Officer



Autifony Therapeutics is developing pharmaceutical treatments for hearing disorders, which affect a significant proportion of the population. Autofony's approach is focused on Kv3 potassium channel modulation, a novel mechanism of action. These ion channels regulate neuronal activity within the auditory system, and our new drugs aim to treat age related hearing loss and tinnitus. The lead programme entered Phase I clinical trials in May 2013.

Given Autofony's focus on modulation of Kv3 channels, which have also been implicated in other neurological and psychiatric disorders, there are opportunities for Autofony to investigate these other indications with compounds with different profiles. Autofony was recently awarded Technology Strategy Board funding to progress the development of a candidate drug for the treatment of schizophrenia, working together with academic collaborators at the Universities of Manchester and Newcastle.

Autifony Therapeutics Limited was formed in 2011 as a spin-out from GlaxoSmithKline. The company is privately funded by leading venture capital investors SV Life Sciences, Imperial Innovations and Pfizer Venture Investments. Autofony's head office is at the Imperial College Incubator in London, and has a subsidiary with medicinal chemistry and biology labs based in Verona, Italy.

www.autifony.com

Avillion LLP



Lewis Cameron, Chief Executive Officer

Allison Jeynes-Ellis, Chief Medical Officer

Avillion was registered in London UK in December 2012 and we are fully financed by the venture capital groups Abingworth and Clarus ventures. We are a company focused on co-development and financing of late-stage programs, where we provide partners with 100% financing for regulatory approval studies with the intent of accelerating the approval of drugs in the US and the EU.

We offer partners an unique and attractive option for the advancement of their pipeline- where we incur 100% of the clinical and regulatory risk of a program, thereby enabling partners to limit their P&L burden and have an advantageous financial position (EPS preservation).

www.avillionllp.com

BIA (UK Bioindustry Association) see page 3

BioPartner UK see page 3

Bristows LLP

Sahar Shepperd, Associate

Matthew Warren, Partner

Bristows is a law firm dedicated to serving businesses with interests in intellectual property and technology, in industry sectors ranging from pharmaceuticals, electronics, IT and telecommunications to consumer products, television and entertainment.

www.bristows.com

Cambridge Bioscience

Vashu Pamnani, Business Manager



Cambridge Bioscience is a well-established, leading European distributor of life science products bringing new and exciting technologies to researchers. Working with over forty specialist suppliers around the world, we offer an innovative, extensive and diverse range of over 450,000 products, services and instruments supporting research in the areas of drug discovery, regenerative medicine, cell culture and much more.

The products and services Cambridge Bioscience offers includes:

- Ion Channel, GPCR & Kinase Profiling Services
- Primary screening & Secondary Drug Profiling Services
- Cardiac Safety Assessment
- Ion Channel & GPCR Cell Lines
- Human Tissues, TMAs & Biofluids
- Primary Cells & Cell Culture Technologies

www.bioscience.co.uk

Canbex Therapeutics

Jesse Schulman, Chief Executive Officer

Keith Powell, Chairman



Canbex is dedicated to improving the quality of life for people with multiple sclerosis (MS) and potentially other disorders, through better treatment for spasticity.

Spasticity is the sudden and uncontrollable movement of limbs and torso, and is among the most painful, damaging and debilitating symptoms of MS. Current drug treatments for spasticity are effective but are plagued by sedative and other side effects that sharply limit their usefulness.

Canbex closed a \$3.2m financing round led by Merck Serono Ventures in April 2013, and its lead anti-spasticity compound, VSN16R, is set to enter Phase I safety testing. In studies to date, VSN16R shows substantially improved tolerability compared to other compounds, and is as effective against spasticity as any other agent known.

Supported by its leading London-based scientific and clinical team, Canbex believes that VSN16R has the potential to meet an important medical need, and to address a highly attractive commercial opportunity.

www.canbex.co.uk

Cddi Ltd

Grahaem Brown, Managing Partner

Eva Hurst, Partner



CDDI is an international biotechnology and pharmaceutical consulting company, led by senior people who together have developed more than 20 products globally from discovery to market. CDDI can give support with a broad range of drug development activities across the three key disciplines of Clinical, Non-clinical and CMC.

Services include Virtual Asset Development (VAD), where CDDI provides a fully integrated development team directed by strong project leadership, Evidence Based Protocol Feasibility (ebf) for data-driven and rapid patient recruitment, and CMC services from API and formulation development of NCEs and NBEs, through to CMO management of GMP manufacturing.

Our working method is hands-on, not just consulting, which means, we don't just advise you, but actively implement the strategies and plans that we formulate with you.

www.cddi.co

Crescendo Biologics

Matthew Roe, Chief Business Officer



Crescendo has developed a unique transgenic mouse which generates fully human VH single domain antibody fragments in the absence of contaminating murine light chains.

VH are the smallest, most robust antibody fragments with advantages for engineering of bispecific and multivalent products, tissue and tumour penetration, topical delivery and simple manufacture.

Crescendo is applying the platform to a pipeline focused on inflammation and oncology, and topical delivery.

www.crescendobiologics.com

CrystecPharma

Catherine Hunter, Business Development Manager



CrystecPharma applies the latest supercritical fluid (SCF) technologies to improve the design and performance of medicines. We provide crystal and particle engineering solutions to the pharmaceutical industry, contributing to human health by enabling new and more effective therapies.

Crystec SCF technologies can be applied to both small drug molecules and biomolecules. Our services include crystal form screening and particle design, addressing issues of poor solubility and stability, improved delivery, and product enhancement in support of lifecycle management.

We are also engaged in in-house programmes to develop improved small and large molecule therapeutic products.

Our objectives this year at BioEurope are to identify new clients wishing to enhance the performance of their small and large molecule therapeutics as well as identifying co-development partners, for supergeneric and new drugs.

www.crystecpharma.com

Datatrial

Lewis Baird, Business Development Manager



Datatrial is an eClinical solutions company, providing comprehensive data management, bio-statistical and consulting services. We have our own proprietary software, nowEDC™ which has been deployed globally in Phase I to Phase III trials. Our ethos is to collaborate with our customers to find and offer solutions that will assist in the achievement of clinical objectives.

www.datatrial.com

Desktop Genetics

Mr Victor Dillard, COO and Founder



Desktop Genetics is a UK-based biotech software company dedicated to making commercial R&D more productive and cost efficient. We develop bespoke workflow tools to simplify the most time-consuming and frustrating challenges facing molecular biologists in genome-editing, disease biology, antibody engineering, cell line development, functional genomics and protein production.

Each tool comprises a collection of functional modules, powered by our proprietary DNA Search Engine technology. To date, modules have let users search for DNA sequences across the world, create an in-lab knowledge base with persistent DNA and oligo sequence data, automatically calculate optimal cloning strategies and repurpose existing DNA. Easily deployed with your existing DNA sequence databases, our technology streamlines and automates workflows so that your skilled personnel can focus on the critical research that drives your business.

Founded by scientists and researchers, our team is experienced with the technical, operational and financial challenges facing molecular biology laboratories today. We are fluent in the languages of biology, programming, and R&D operations, ensuring your needs are translated into a superior business and research tool. We look to partner with life science companies to deploy existing modules and develop new ones from the ground up. Get in touch with us today to discuss how we can help make your DNA work for you.

www.deskgen.com

Domainex

Eddy Littler, Chief Executive Officer

Joanne McCudden, Head of Business Development



Domainex is a drug discovery company with a reputation for speed and innovation built on an exceptional track record of drug candidate delivery. It has a world class discovery team with an unrivalled track record and three client drug candidates already in clinic.

Domainex reduces industry average drug discovery timelines by as much as 30% through the application of novel proprietary technologies and a highly focussed and integrated approach to medicinal chemistry and computational chemistry. These technologies and Domainex's approach also enable it to successfully tackle a greater range of drug target classes, such as kinases, proteases, ion channels, proteins involved in epigenetics and protein-protein interactions.

Domainex has applied its unique technologies and focussed discovery approach to enable it to develop its own pipeline of oncology drugs, including inhibitors of the kinases IKKε/TBK1 for both oncology and inflammation and a number of epigenetics related lysine methyltransferases, including G9a
www.domainex.co.uk

Epistem

Andrew Carnegie, Business Development Manager
Jeremy Kamaluddin, Business Development Director



Epistem is a biotechnology company with a specialist understanding of epithelial tissue and stem cell analyses, operating three distinct business divisions.

The Contract Research Division delivers innovative preclinical research services in the areas of oncology (inc. leukaemia), mucositis, inflammatory bowel disease, rheumatoid arthritis, wound healing and skincare. Working with over 200 pharmaceutical, biotechnology, and personal care companies worldwide, it offers proprietary assays for target validation, screening, efficacy, and translational biology using some of the latest technology, including small animal imaging, and with a GCLP accredited histology suite.

The Personalised Medicine Division is committed to facilitating a more tailored approach to patient treatment and care. It applies innovative gene expression technology to discovering novel drug-induced biomarkers to GCLP standard. It has also developed Genedrive™, a 'point of care' molecular diagnostic device providing a 'near patient' diagnosis in less than 30 minutes using hand held apparatus.

Our Novel Therapies Division is identifying the key regulators (proteins and peptides) of epithelial stem cells with the aim of developing therapeutics to control cell production.

www.epistem.co.uk

e-therapeutics



e-Therapeutics is an AIM-listed biotechnology company with a proprietary platform in network pharmacology, an innovative new approach to drug discovery based on advances in network science and chemical biology. The Company's discovery and development activity is focused in cancer and disorders of the nervous system. The firm has two drugs in the clinic: ETS2101, which is in phase I trials for cancer; and ETS6103, which is in phase II trials for major depressive disorder. e-Therapeutics is based at sites in Oxford and Newcastle, UK.

www.etherapeutics.co.uk

Galen Ltd see Almac Group

Genetic Microdevices

Dimitris Sideris, Chief Executive Officer



The company develops companion diagnostic tests and biomarker discovery platforms based on its unique analytical technology, the CycloChip™. The tests come in the form of disposable cartridges specific to desired applications. Direct comparative studies, have shown that the technology is between 30x-270x times faster, with over 10x higher resolution and 2000x more sensitive than competing top of the range analytical instruments. The fact that this performance can be achieved in disposable devices that can be flexibly customised to different diagnostic and analytical applications, makes this device very attractive diagnostic companies and CROs.

GMD is looking for end-users of the technology to tailor the disposable cartridges to their specific needs. The GMD system can be applied to both proteomic and genomic analyses. GMD is looking for a partner/end user to out license its technology and at the same time develop its product portfolio driven by the specific needs of the end-user. The latter could be a pharmaceutical company with internal R&D or a diagnostic company. GMD is based at Kingston University, London. Its technology has been awarded multiple prestigious grants, from the London Development Agency and Technology Strategy Board.

www.genetic-microdevices.co.uk

Glythera

David Simpson, Chief Operating Officer



Glythera is an emerging biotechnology company specializing in the development of next generation biotherapeutics through the application of its advanced proprietary conjugation and glycosylation technologies.

Located in the North East of the UK with its dedicated bioprocessing and chemistry development laboratories at Newcastle University, Glythera is positioned as a critical partner in any development program centred on its PermaLink™ and PermaCarb™ technologies. Our PermaLink™ platform supports highly selective site specific conjugation whilst demonstrating significantly increased stability with our core focus being in the development of enhanced Antibody Drug Conjugates and bi-specifics. Glythera's PermaCarb™ technology allows direct substitution of endogenous glycan's or correction of micro-heterogeneity using stable analogues to improve bioavailability and efficacy and has been demonstrated in a range of next generation biotherapeutics. Our Mission is to enable improved clinical regimes through the creation of the next generation of safe, efficacious biotherapeutic products in oncology and therapeutic indications.

www.glythera.com

Hypha Discovery

Liam Evans, Chief Executive Officer



Hypha collaborates with pharma/biotech and agrochemical groups in the following areas

1. Production of metabolites of clinical and preclinical stage compounds that are difficult to synthesise using metabolising microbes:
 - + mg amounts for MetID, quantification standards
 - + gram quantities for tox/pharmacological studies
 - + includes glucuronides and chemically intractable hydroxyl derivativesOur microbial biotransformation service is also used to improve PK/solubility in hit-to-lead compounds
2. Niche natural products hit-finding
Licensing access to Hypha's MycoDiverse natural products library.
 - + Used by biotech and pharma to find compounds against difficult-to-hit targets
 - + Molecular weight range mostly between 200 and 400 DA
 - + 50% novelty
 - + Exclusive rights to develop and commercialise
3. Fermentation and purification of small molecules for semi-synthetic lead optimisation

www.hyphadiscovery.com

Illingworth Research

Kieran Casey, Director Business Development



Founded as Clinical Development & Support Services Ltd (CDSS) in 1998, Illingworth Research is a Clinical Research Organisation (CRO) providing a wide range of clinical development services to the pharmaceutical, healthcare, biotechnology and medical device industries. We are experts in the management of Phase I to IV clinical trials across many different therapeutic areas. From our base in Cheshire UK, where we are co-located with our sister company ResearchNurses.co, we offer the ultimate clinical research outsourcing partnership for sponsors across the globe. We have worked with all types of clients, from start-up biotechnology companies to large international pharmaceutical companies, providing strong sponsor/CRO partnerships to deliver a competitive advantage.

www.illingworthresearch.com

Image Analysis

Aidan Ancill, Head of Operations and Business Solutions



'Effective use of imaging to understand if the drug works'

We offer advanced medical image analysis techniques and propriety technology platform to improve study economics, to facilitate greater quality control and objectivity of the outcomes.

Image Analysis team support Sponsors in setting up technology supported clinical studies , where image scoring is done using computer-aided algorithms and image management is standardized, automated and centralized with the company's proprietary platform Dynamika.

www.imageanalysis.org.uk

MGB Biopharma

Miroslav Ravic, Chief Executive Officer

Raymond Spencer, Chief Financial Officer



MGB Biopharma is a private company based in Glasgow, Scotland and is backed by a syndicate of Scotland's leading angel investor groups together with Scottish Enterprise. MGB is developing the first truly novel class of anti-infectives in over a decade that has the potential to treat infections of a number of the most important susceptible and resistant pathogens. Our lead compound has shown strong bactericidal activity with quick onset of action against many strains of Gram-positive bacteria. It has completed pre-clinical development and progress into our phase 1 clinical study for the treatment of Clostridium difficile have been endorsed by the MHRA. Optimisation of a new formulation for intravenous administration and treatment of systemic Gram-positive infection is ongoing.

MGB has acquired exclusive rights to the proprietary minor groove binder platform, developed at the University of Strathclyde, Glasgow. This platform provides an opportunity to develop additional compounds with the potential to treat Gram-negative, viral, fungal and parasitic infections.

MGB continues to work closely with Strathclyde University to develop the pipeline and is currently seeking partners to help maximise the value-creating opportunities from its broad platform.

www.mgb-biopharma.com

MiNA Therapeutics

Mr Robert Habib, Chief Executive Officer



MiNA Therapeutics is a virtual biotechnology company pioneering the activation of gene expression with short activating RNA (saRNA).

Harnessing a proprietary algorithm, MiNA is developing a revolutionary class of therapeutics that activate key genes in major disease pathways. MiNA's ability to selectively activate master regulatory genes represents a new frontier in precision medicine. MTL-501 is a saRNA liver cancer therapeutic that activates the CEBPA gene. Intravenous injection of MTL-501 in a liver cancer rat model reduced tumour burden by 80% whilst increasing significantly serum albumin. In vitro work has indicated the dramatic potential of CEBPA saRNA as a universal anti-cancer therapeutic in non-small cell lung, prostate, pancreas, leukaemia, lymphoma and glioblastoma. MTL-301 is a Type 1 diabetes therapeutic. In vitro work demonstrated glucose responsive insulin secretion by both CD34+ adult stem cells and HepG2 cells.

www.minatx.com

Nova Language Services

Arun Matthew, Sales Executive Europe



Are you on the lookout for a specialised Localization and multilingual translation partner who can handle 100 plus language combinations?

Can supply certified translations under UNE 15038 and ISO9001 has 14 years' experience working in pharma, medical device and clinical trial sectors.

Can understand the importance of a quality process and critical attention to detail under tight timelines with competitive pricing!

Is Big enough to meet your needs but small enough to care!

Look no further lets' meet at Bio Europe 2013 and discuss how NOVA could help you with your translation and interpretation requirements.

Also see our advertisement on the inside front cover of this brochure.

www.novatransnet.com

Novozymes Biopharma

Dave Mead, Business Development Director

Tara Sharpe, Business Development Manager



Novozymes Biopharma develops and manufactures sustainable, safe, biological based ingredients and technologies to provide pharmaceutical and medical device manufacturers the knowledge-based solutions needed to address the challenges in developing innovative, safer, and more consistent final products. The company's large-scale manufacturing facilities worldwide are run to cGMP Q7 quality standards to ensure that customers receive the highest level of product quality and consistency, as well as the security of long-term supply. Novozymes' customer-integrated approach combines the company's scientific know-how and the specific needs of customers to deliver improved products and performance. By combining Novozymes' unique knowledge around our biological solutions such as recombinant albumin, half-life extension and hyaluronic acid with the specific application knowledge of our customers, we work with companies to deliver improved performance and safety for next generation of medical device and pharmaceutical products.

www.biopharma.novozymes.com

Ockham Oncology

Andrea Cotton-Berry, Global Director, Client Services
Mike Baker, Vice President



Ockham provides high-quality, global clinical research and strategic development services to pharmaceutical and biotechnology companies, assisting them in the achievement of their strategic planning, technology transfer, licensing, regulatory planning and submissions, pre-clinical development, and manufacturing goals.

Ockham also provides fully integrated clinical trials support in the areas of Clinical Operations, Data Management and Biostatistics, as well as Regulatory dossier compilations. In addition, it offers functional and specialty resourcing services to pharmaceutical, biotech and medical device companies that require Clinical Operations, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), or Good Manufacturing Practice (GMP) auditing, Data Management, Statistical Programming, Biostatistics, and Medical Writing solutions.

www.ockham.com

Oxford Biomedica plc

Alex Lewis, Director of Corporate Activities & Strategy
Peter Nolan, SVP - Commercial Development



Oxford BioMedica (LSE:OXB) is a leading gene therapy and immunotherapy company with a platform of exclusive and pioneering technologies to design, develop and manufacture unique gene-based medicines. The Company's technology platforms include a highly efficient LentiVector® gene delivery system; a single administration to provide long-lasting therapy with specific advantages for targeting CNS and ocular diseases, and a unique tumour antigen (5T4) which is an ideal target for anti-cancer therapy.

The Company's pipeline addresses diseases for which there is currently no treatment or that are inadequately treated today, including ocular diseases, neurodegenerative disorders and cancer, and its product candidates have the potential to transform treatment landscapes. Oxford BioMedica's capabilities cover the entire product lifecycle, from research to development to GMP manufacturing, with collaborative partners such as Sanofi, Pfizer, Novartis and some of the most prestigious clinical centres worldwide.

The Company recently secured significant funding via UK Government competitive awards such as the TSB regenerative medicine/cell therapy grant and AMSCI to build a centre of excellence for specialist manufacture of gene-based therapies.

Through in-house development programmes and industry collaborations, Oxford BioMedica's goal is to improve the lives of patients with debilitating and life-threatening diseases.

www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk

Purolite

Alessandra Basso, LifeTech Manager



A leader in ion exchange and resin technology—and one of the world's largest developers and manufacturers of high-quality APIs, blood purification polymers, enzyme carriers, chromatographic resins and ion exchange products—Purolite is introducing the new product line based on agarose in our cGMP, FDA regulated facility.

With three strategically located production plants, five global R&D centers—including a research center of excellence in the UK—and a sales force made up of industry experts, Purolite is your solutions company for quality products, stability of manufacturing and knowledgeable service.

Developed and manufactured by Purolite, innovative agarose-based biochromatography resins will expand the LifeTech family of products to cover SEC, HIC, IEX and affinity bio-purification media for the fast-growing biosimilars market.

LifeTech bio-based resins will support customer needs—from drug development with pre-packed columns, to bulk media for industrial production of biosimilars.

www.purolite.com

QCTR

Audrey Jamieson, Business Development Manager



QCTR is the ONLY CRO to focus exclusively on clinical trials in CNS. With its subjective assessments and often subjective diagnosis, along with lack of biomarkers and high placebo response, CNS offers unique challenges. QCTR have over 15 years of experience in CNS covering diseases as diverse as Alzheimer's, TBI, stroke and schizophrenia, and orphan diseases such as Huntington's and FTD.

With a worldwide network of experienced clinicians working in neurology and psychiatry, and experienced staff knowledgeable in the therapeutic field, we can plan and execute cost effective clinical trials to meet your company's specific requirements.

www.qctr.co.uk

Quay Pharma

Michael Kruidenier, Business Development Manager

Mairaedh Pedersen, Chief Executive Officer



Quay Pharma is one of the world's leading Contract Development and Manufacturing Organisations, or CDMOs. Based in the UK, we provide specialist services to the pharmaceutical and biotech industries built on our unique expertise in drug formulation development, analytical services and contract manufacturing.

Quay provides formulation, analytical development and clinical trials manufacturing for companies world-wide. Applying strong project management, products are quickly and cost effectively taken from pre-clinical through phase II trials. Having deep knowledge in solid dosage form development, particularly improving bioavailability of NCEs, has resulted in many clients successfully licensing products on to large pharmaceutical companies.

www.quaypharma.com

Selcia

Dave Roberts, Business Development Director, Radiochemistry



Selcia Ltd is a leading provider of contract research services in drug discovery and ¹⁴C radiolabelling.

Selcia drug discovery provides integrated drug discovery services to support academics, institutions, biotech and pharma companies. Selcia assist in grant applications; execute the medicinal chemistry to deliver the best drug candidates, provide supporting project management and primary pharmacology, to ensure project success.

Selcia radiolabelling specialises in ¹⁴C GMP radiolabelling and produces ¹⁴C radiolabelled compounds for a global customer base encompassing both the life sciences and chemical industries. Applications of the radiolabelled products prepared by Selcia include: preclinical and clinical drug metabolism studies; mass balance, microdosing, research and regulatory studies; and environmental fate studies.

The purity and structure of our products are assured by our internal MHRA GLP accredited analytical department with 500MHz, 400MHz & 300MHz NMRs, mass spec and separation specialists. The group are experts in problem resolution to ensure projects meet agreed milestones.

Areas of Expertise

Medicinal chemistry: Small molecules, macrocycles, natural product chemistry

Disease expertise: Anti-infectives, inflammation, CNS, pain, metabolic

Target classes: GPCRs, ion channels, enzymes, isomerases

¹⁴C Custom Radiosynthesis

GMP Radiolabelled API for Clinical Trials

GLP/GMP Analytics – GLP NMR

Metabolites and Impurities (Profiling and Synthesis), standards and stable labelled compounds

www.selcia.com

Sphere Fluidics

Rob Marchmont, Commercial Director

David Holmes, Principal Engineer



Sphere Fluidics Limited is an innovative Life Sciences company which delivers miniaturised products, systems and collaboration services in field of single cell analysis.

Sphere's core technology is in the field of high throughput Picodroplet generation and analysis and has significant patent portfolio that protects its core expertise. It enables ultra-high throughput analysis of single cells and generation of their genetic, transcriptomic and proteomic profiles in miniaturised (pl to nl) volumes. Uniquely, as well as allowing single cell studies, the systems enable the study of different, large biomolecules that interact with or are secreted by those single cells. The latter application is very powerful as many human biotherapeutics, industrial enzymes (isolated mainly from micro-organisms) and around 15% of the Human Proteome are secreted, so cannot readily be analysed using conventional technology.

Sphere Fluidics' technology enables diverse applications such as study of the mechanism of cancer cell resistance to chemotherapy, generation of new enzymes and identification of novel microbial strains. Sphere Fluidics has established multiple commercial partnerships, received Venture Capital investment and with its founders the Company have received almost £10 million in science and business funding to date.

www.spherefluidics.com

Sygnature Discovery

Paul Clewlow, SVP, Business Development and Director



Sygnature Discovery, founded in 2004 in Nottingham, UK, is a leading provider of integrated drug discovery services to pharmaceutical companies, biotechs and academics located in Europe and the USA. Through its unique 'federated' CRO model, Sygnature undertakes complete drug discovery programmes and hit finding, hit-to-lead and lead optimisation projects for its clients. The company employs 75 laboratory-based, industry-experienced PhD medicinal chemists, computational chemists and in vitro biologists.

Working within the highly-complex, competitive and fast-paced pharmaceutical and biotech sectors, Sygnature has developed a unique approach to offering a premium integrated drug discovery service – the delivery of in-depth, pharmaceutical industry-derived drug discovery expertise and flexible FTE-based resource housed in a ‘state-of-the-art’ R&D facility, but at a cost effective price. From the outset, Sygnature has operated a business whose primary focus has been value creation for its clients, through the application of drug discovery expertise, close working relationships and complete transparency.

To facilitate the delivery of top quality drug discovery services to its clients, Sygnature has strategic alliances with Cyprotex Discovery (ADME/toxicology), Saretius (pre-clinical pain/CNS and metabolic disease models), Pneumolabs (pre-clinical respiratory models), Horizon Discovery (X-Man™ isogenic cell lines), ChanTest (ion channel experts) and Proteros (X-ray protein structure analysis).

www.sygnaturediscovery.com and www.integrateddrugdiscovery.com

Synpromics

Dr Michael Roberts, Chief Executive Officer



Synpromics is a life science company focused on synthetic biology. Our core proprietary technology enables the design of optimized Synthetic Promoters to more effectively and efficiently regulate gene expression throughout biotechnology applications. Via product-development and distribution partnerships, Synpromics will commercially apply our novel promoters to enhance and expedite life science R&D, improve biology-based production processes, advance agricultural biotech and progress personalized medicine.

www.synpromics.com

UK Trade & Investment see page 4

To do list:

Get discount for Biotech Showcase entry. Apply for Presentation slots and £1500 grant at:

<http://www.biopartner.co.uk/events.php#event:413>

Get discount for BioEurope Spring entry. Register at:

<http://www.biopartner.co.uk/events.php#event:416>

Index of UK Company Types

Members of the UK delegation are showcased at the UK stand 68. Others can be contacted via the online partnering system or after the event by contacting: enquiries@biopartner.co.uk

BioTherapeutics

Activiomics
Almac Discovery
Antitope Ltd
Apitope
Atebion BDS Ltd
Autifony Therapeutics Ltd
Bicycle Therapeutics Limited
BiotecnoL, Ltd
Canbex Therapeutics Ltd
Cancer Research Technology
Cell Medica
Circassia
Crescendo Biologics
Domainex Ltd
Ergomed Clinical Research Ltd.
e-Therapeutics plc
F-star
Gilead Sciences
GT Biologics Ltd
Haemostatix Ltd
Heptares Therapeutics
Immune Targeting Systems
Immunocore
Isogenica
Kymab Ltd
MGB Biopharma Limited
Midatech Group
MiNA Therapeutics
Moorfields Pharmaceuticals
Ockham Oncology
Oxford BioMedica plc
Oxford BioTherapeutics
Oxyrane
PlaqueTec Ltd
PolyTherics Ltd
ProFactor Pharma Ltd
Proxima Concepts/Diabetology
PsiOxus Therapeutics Ltd.
Sareum Ltd
SGS VITROLOGY
Shield Therapeutics
Summit Corp plc
Thiologics Ltd
TPP Global Development Limited
University of Sussex Translational Drug Discovery Group
Valirx
Xention Ltd

Pharma

3M Health Care Limited
Acacia Pharma
Allergan Holdings Ltd
Amdipharm Mercury Co. (AMCo)
AstraZeneca
Atlantic Healthcare plc
Aurelia Bioscience
Bio-Images Group
Bristol-Myers Squibb
Consilient Health
CrystecPharma Ltd.
Eisai
Galen Ltd
Glide Pharma
GW PHARMACEUTICALS
Illingworth Research
Mundipharma International Ltd
Nanomerics
Norgine Ltd
Ono Pharma UK
ORBONA Pharma Ltd
Plethora Solutions
Prosonix
ProStrakan
Q Chip Ltd
Redx Pharma Ltd
Shire
Teijin Pharma Ltd
UCB Celltech
Vectura
Warner Chilcott UK, a division of Actavis Inc.

Public/Non-Profit

BioIndustry Association (BIA)
BioPartner UK
Edinburgh BioQuarter
EMBL-European Bioinformatics Institute (EBI)
Kings college London
MRC Technology
Newcastle Biomedicine
One Nucleus
Queen Mary University
Scottish Development International
Strathclyde University
The Institute of Cancer Research
UCL Business PLC
UK Trade & Investment - London Region
University of Dundee, Research & Innovation Services
University of Nottingham
Wellcome Trust Sanger Institute

Medical Technology

Endomagnetics Ltd.
GE Healthcare Lifesciences
Genetic Microdevices Ltd
Heraeus
VueKlar Cardiovascular Ltd.

Services and Consulting

80th Atom Ltd
Advocates Ltd
Alacrita
Apex healthcare Consulting Ltd
Appleyard Lees
Bristows LLP
Clinigen
College Hill Life Sciences
Competitive Drug Development International Ltd
Coulter Partners
Covington & Burling LLP
Current Partnering
Decision Resources Group
Desktop Genetics
Egamid Ltd
ERA Consulting UK Ltd.
Ferghana Partners
Fidelity Biosciences
george james ltd
Gleacher Shacklock
GLG (Gerson Lehrman Group)
GlobalData Group
Informa
Informa telecoms & media
Liftstream
Medius Associates
Mewburn Ellis LLP
NDA Group
Nova Language Services Ltd
PharmaVentures
PharmaWave Ltd
Phastar
Present Value Ltd
ProPharma Partners Limited
Quintiles
R&D Focus/IMS Health
Sage Healthcare Ltd
Talentmark
Thomson Reuters
Warwick Ventures

Media

BioPharm Insight
IMS Health
Nature Publishing Group
PharmaTelevision

Investor

Entrepreneurs Fund
MVM Life Science Partners
Visium Asset Management

R&D Services

Almac Group
AMRI UK
Aptuit Glasgow
Avillion LLP
BioFocus
BioOutsource Ltd.
Biopharma Technology Ltd
BioReliance
Brainwave-Discovery Ltd.
Cambridge Bioscience Ltd
Cmed Clinical Services
Covance Laboratories Ltd
CytoPathfinder, Inc./ PGXIS Limited
Datatrial Limited
Epistem Ltd
FinVector Vision Therapies Ltd
Fujifilm Diosynth Biotechnologies
Fusion Antibodies
Glythera Ltd
HitGen Ltd
Hologic | Gen-Probe
Horizon Discovery
Hypha Discovery Ltd
ICT Biosciences
Image Analysis Ltd
INC Research
KWS BioTest
MOFgen Ltd
Molecular Profiles
NextPharma
Novella Clinical
Novozymes Biopharma UK Ltd
Patheon
Peakdale Molecular Ltd.
Pharmaterials Ltd
PRA
ProlImmune Ltd
Purolite
QCTAR Ltd
Quay Pharma
Roslin Cells Limited
RUSSLAN Clinical Research
Selcia Ltd
Sphere Fluidics Ltd.
Synnature Discovery Limited
Synpromics Ltd
SYNthesis med chem
Theradex Europe
TRN - The Research Network Limited



BioPartner UK is an independent, accredited trade organisation, funded by membership fees; promoting international partnering for trade, investment and collaborations with UK life science companies.

BioPartner promotes the UK presence at international conferences. Joining a UK Delegation gives your company significant extra promotion and networking opportunities at many of the biggest biopharma events. BioPartner also provides membership services, access to government grants and enhanced entry fee discounts for UK SMEs.



BioPartner is a founder member of UK BiotechNet, the UK Life Science expertise consortium that sets you up for business in the UK.

www.biopartner.co.uk

www.biotech.net.co.uk

BioPartner UK, St James House, 13 Kensington Square, London W8 5HD